FindTrial
Sign In

Study on the effect and mechanism of Xuebijing on inflammatory response of PATIENTS treated with ECMO

Study on the effect and mechanism of Xuebijing on inflammatory response of PATIENTS treated with ECMO

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100054069
Enrollment
Unknown
Registered
2021-12-08
Start date
2021-12-14
Completion date
Unknown
Last updated
2022-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myocardial infarction

Interventions

experimental group:xuebijing
control group:placebo

Sponsors

Affiliated hospital of Qingdao university
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Patients aged 18 to 75 admitted to the Intensive Care Department of Qingdao University Affiliated Hospital; 2.Patients diagnosed as acute myocardial infarction with cardiogenic shock were treated with ECMO.

Exclusion criteria

Exclusion criteria: 1. Have a history of allergy to Xuebijing; 2. Any confirmed or suspected immunosuppression or immunodeficiency status; 3. Patients with known or suspected infection at the time of admission.

Design outcomes

Primary

MeasureTime frame
mortality;—

Secondary

MeasureTime frame
cytokines;—

Countries

China

Contacts

Public ContactYuan Zhiyong

Affiliated Hospital of Qingdao University

276874098111999@163.com+86 18661806623

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 5, 2026